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Abstract 
Vincristine, oxaliplatin, and cisplatin are commonly prescribed chemotherapeutic agents for the 
treatment of many tumors. However, a main side-effect is chemotherapy-induced peripheral 
neuropathy (CIPN), which may lead to changes in chemotherapeutic treatment. Although 
symptoms associated with CIPN are recapitulated by mouse models, there is limited knowledge 
of how these drugs affect the expression of genes in sensory neurons. The present study carried 
out a transcriptomic analysis of dorsal root ganglia (DRG) following vincristine, oxaliplatin, and 
cisplatin treatment with a view to gain insight into the comparative pathophysiological 
mechanisms of CIPN. RNA-Seq revealed 368, 295 and 256 differential expressed genes (DEGs) 
induced by treatment with vincristine, oxaliplatin and cisplatin, respectively and only five shared 
genes were dysregulated in all three groups. Cell type enrichment analysis and gene set 
enrichment analysis showed predominant effects on genes associated with the immune system 
after treatment with vincristine, while oxaliplatin treatment affected mainly neuronal genes. 
Treatment with cisplatin resulted in a mixed gene expression signature.  
Perspective 
These results provide insight into the recruitment of immune responses to DRG and indicate 
enhanced neuro-inflammatory processes following administration of vincristine, oxaliplatin, and 
cisplatin. These gene expression signatures may provide insight into novel drug targets for 
treatment of CIPN. 
Key words: neuro-inflammation, pain, anti-neoplastic agents, gene expression profile, 
transcriptome 
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Introduction 
Chemotherapy-induced peripheral neuropathy (CIPN) is an unfortunate side-effect of many anti-
cancer therapies Quasthoff and Hartung [62]. In particular, patients receiving vincristine, 
oxaliplatin or cisplatin develop numbness, tingling, loss of reflexes, ataxia, and pain [67]. These 
dose-and time-dependent side-effects are characteristic of CIPN and can be so problematic that 
treatment cessation is required [59]. Unfortunately, there are no effective strategies for the 
treatment or prevention of CIPN symptoms despite the continued use of these highly effective 
cancer medications. Although these anti-cancer medications have diverse mechanisms of action - 
vincristine inhibits the assembly of β-tubulin [21], while the platinum derivates oxaliplatin and 
cisplatin bind to DNA and interfere with replication, transcription and cell cycle [1; 12; 19; 87] - 
all agents are defined by a predominantly peripheral sensorimotor neuropathy that includes 
sensory, motoric and autonomic symptoms (Table 1). 
Sensory symptoms – including hypoesthesia, paresthesia, burning sensation, neuralgia, myalgia 
and decreased vibration sense – occur in patients receiving vincristine, oxaliplatin or cisplatin. 
Interestingly, although cisplatin and oxaliplatin are closely related structurally, the symptoms 
induced by these agents suggest divergent pathophysiological mechanisms, as oxaliplatin elicits 
characteristic cooling-induced dysesthesias that are not typically induced by cisplatin. 
Vincristine and oxaliplatin but not cisplatin additionally induce hyperesthesia, jaw pain and 
arthralgia, while gait abnormalities or difficulty walking are characteristic of motoric dysfunction 
and develop after treatment with all three drugs. However, muscle weakness seems to develop 
specifically after treatment with vincristine or oxaliplatin (Table 1). In addition, patients treated 
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with vincristine develop frequent autonomic symptoms, including paralytic ileus, postural 
hypotension and urogenital dysfunction [53]. 
Although the pathophysiological mechanisms leading to CIPN induced by vincristine, oxaliplatin 
and cisplatin have been studied extensively and appear to involve altered calcium homeostasis of 
neurons, mitochondrial dysfunction and inflammatory processes (for review see [71]), a 
comparative analysis of gene expression changes in dorsal root ganglion neurons induced by 
these agents is lacking.  
In the past, transcriptomic analysis of neuronal tissue has greatly extended our understanding of 
pain mechanism and progression [66; 70]. These techniques allow an understanding of the 
genomic and molecular responses of cells to pathological conditions, including the response of 
neurons and immune cells to chronic painful stimuli [70]. Therefore, we sought to compare the 
gene expression profile of dorsal root ganglia after treatment with vincristine, oxaliplatin or 
cisplatin to gain insight into the mechanisms of CIPN development. Overall, vincristine-induced 
gene expression changes were consistent with predominantly inflammatory processes, while 
treatment with oxaliplatin led to altered expression of genes associated with neuronal damage. 
Furthermore, cisplatin caused gene expression changes consistent with a mixed inflammatory 
and neuropathic phenotype.  
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Methods 
Animal ethics 
Ethics approval for in vivo experiments was obtained from the University of Queensland Animal 
Ethics Committee. All experiments were conducted in accordance with the Animal Care and 
Protection Act Qld (2002), the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes, 7th edition (2004) and the International Association for the Study of Pain 
Guidelines for the Use of Animals in Research. 
Induction of chemotherapy-induced neuropathy and behavioural assessment 
Vincristine (Sapphire Bioscience), oxaliplatin (Sapphire Bioscience) or cis-
Diammineplatinum(II) dichloride (cisplatin, Sigma Aldrich) were administered as described 
previously [13; 15]. Briefly, 8-10 week old C57BL/6J mice were injected i.pl. with vincristine, 
oxaliplatin or cisplatin or with 5% glucose (control group) under 3% isoflurane anaesthesia and 
allowed to recover in their home cages. The injection schedules and the time of tissue collection 
were chosen based on previous studies and reports of vincristine, oxaliplatin and cisplatin 
induced neuropathy symptoms [13; 15; 55].  Vincristine (10 µg; i.pl.) was administered once a 
day for four days and DRGs were collected on day 7 (cumulative dose 40 µg). Oxaliplatin and 
cisplatin were injected once (40 µg; i.pl.) and tissue was collected after 72 hours.  
Mechanical, thermal and cold allodynia were quantified as previously described [13; 14]. In 
brief, mechanical allodynia was assessed using an electronic von Frey apparatus (MouseMet, 
TopCat Metrology), which automatically determines the paw withdrawal threshold (PWT) upon 
linear increase of force applied via a blunt-tipped monofilament. Mice were acclimatized to 
individual enclosures in which animals stand on parallel bars, making the plantar surface of the 
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hind paws freely accessible to the von Frey filament. Three readings, taken at least 5 min apart, 
were averaged to obtain the PWT for each animal.  
Heat allodynia was quantified using the Hargreaves test, in which animals are acclimatized to 
plexiglass enclosures positioned on a pre-warmed glass plate. A radiant heat source (IITC Life 
Science Plantar Test), directed at the plantar surface of the hind paws, was used to elicit paw 
withdrawal, with the pre-determined cut-off set to 20 sec to avoid tissue damage.  
Cold allodynia was quantified by counting the number of paw lifts, licks and flinches over 5 min 
in animals allowed to freely move on a Peltier-cooled plate maintained at 10 °C. All behavioural 
quantifications were carried out by a blinded observer who was unaware of the treatments 
animals had received. 
Sample preparation for RNA-Seq analysis 
Mice were euthanized 48 hours after i.pl. injection of vincristine, oxaliplatin or cisplatin using 
carbon dioxide, and the lumbar dorsal root ganglia (DRGs) at L3, L4 and L5 were dissected as 
described previously [83]. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Melbourne, Australia, including on-column DNase digestion). To obtain sufficient amount of 
RNA, DRGs from four animals were collected and pooled to obtain one biological replicate. 
Three biological control replicates and three vincristine, oxaliplatin or cisplatin treated replicates 
were used for RNA-Seq.  
RNA-Seq 
RNA-Seq, including bioinformatics analysis, were performed by the Institute for Molecular 
Bioscience Sequencing Facility (The University of Queensland, Brisbane, QLD, Australia). 
RNA-Seq was performed on the Illumina NextSeq 500 platform using 75-nucleotide single-end 
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runs. Libraries were constructed using TruSeq stranded total RNA library preparation and the 
reads were mapped to Ensembl Mus musculus mm10 genome (version GRCm38) using STAR 
aligner (version star/2.3.0 e) [17]and samtools [38]. The counts were generated using the HTSeq 
package [3] and the list of differential expressed genes was created using the R (version 3.2.2) 
package DESeq2 [45].  
Bioinformatics analysis 
The volcano plots were generated using the R package ggplot2. The list of genes was ranked by 
adjusted p-value (Padj), and only genes with Padj < 0.05 and total log2-fold change of > 1 were 
considered to be differentially expressed and used for further analysis. Cell type enrichment 
analysis was performed using the CTen tool as described previously [68]. The score was 
generated using one-sided, Fisher's Exact test for enrichment and it is shown as the -log10 of the 
Benjamini-Hochberg (BH) Padj. Scores > 20 optimally minimize the false positive rate (FPR). 
Each list of differentially expressed genes (DEG) was analyzed separately. Gene set enrichment 
analysis (GSEA) was conducted using GSEA Java desktop application and Molecular Signature 
Database (MSigDB) [72]. Overlaps between differentially expressed genes and C5 curated gene 
set (Biological process) were computed with FDR q value setting < 0.05 and top 20 or 60 gene 
set overlaps were shown. The functional protein association network analysis was performed 
using STRING database [73] and only interactions with medium or high confidence were shown; 
proteins were clustered using the Markov Cluster Algorithm with inflation parameter of 1.8 [7]. 
The gene identifiers were converted into gene names using DAVID Bioinformatics Resources 
6.8, NIAID/NIH the Gene Name Batch Viewer tool. Lists of differentially expressed genes or 
GO biological terms were compared using the Molbiotools, multiple list comparator 
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(http://www.molbiotools.com/listcompare.html). Data is available at the Gene Expression 
Omnibus (GEO submission number: GSE125003).  
 
Results 
Vincristine, oxaliplatin and cisplatin induce neuropathy symptoms in mice 
To confirm development of peripheral neuropathy after administration of vincristine, oxaliplatin 
and cisplatin, and to directly compare the behavioural phenotypes induced by these agents, we 
first assessed mechanical, heat and cold allodynia. As previously described, all three agents 
elicited robust mechanical allodynia (Figure 1A), with paw withdrawal thresholds decreasing 
from 3.2 ± 0.1 g (control group) to 1.0 ± 0.3 g (oxaliplatin, P < 0.05), 1.1 ± 0.2 g (cisplatin, P < 
0.05) and 1.6 ± 0.1 g (vincristine, P < 0.05) within 24 h of injection. In contrast, heat withdrawal 
thresholds were unchanged from control (10.2 ± 1.0 s) after treatment with oxaliplatin (9.0 ± 1.6 
s); decreased after treatment with cisplatin (6.0 ± 0.2 s, P < 0.05) and increased after treatment 
with vincristine (16.5 ± 0.9 s, P < 0.05) (Figure 1B). Only oxaliplatin (90.7 ± 6.1 flinches) 
caused cold allodynia, while no cold-induced responses were observed in either vehicle-treated 
animals (0 ± 0 flinches), cisplatin-treated animals (0 ± 0 flinches) or vincristine-treated animals 
(2.2 ± 1.0 flinches) (Figure 1C). 
Comparison of vincristine-, oxaliplatin- and cisplatin-induced changes in gene expression 
In order to gain more insights into mechanism underlying the development of vincristine-, 
oxaliplatin- or cisplatin-induced peripheral neuropathy, and to compare the substance-specific 
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effects on peripheral neurons, we performed a transcriptome of mouse lumbar dorsal root ganglia 
(L3-L5) after administration of vincristine, oxaliplatin or cisplatin (GEO submission number: 
GSE125003).  
Treatment with vincristine caused a significant (Padj < 0.05) differential expression of 368 genes, 
323 of which were up-regulated, with only 45 down-regulated (Figure 2A & 2B) (For full list of 
DEGs following vincristine administration see Supplementary Table S1). Among the highly 
down-regulated genes (log2fold change < - 1) was Ms4a1, which encodes Membrane Spanning 
4-Domains A1, also called CD20 antigen; a B-lymphocyte antigen. Highly upregulated DEGs 
(log2fold change > 1) included Nts (Neurotensin), Atf3 (Activating Transcription Factor 3), 
Sprr1a (Small Proline Rich Protein 1A), Ecel1 (Endothelin Converting Enzyme Like 1), Cckbr 
(Cholecystokinin B Receptor) and Star (Steroidogenic Acute Regulatory Protein), which have all 
been associated with altered pain perception, neuropathic pain and neuronal injury in previous 
studies [11; 30; 34; 46; 49; 51; 83]. The direct and secondary interactions between DEGs 
following vincristine administration are shown in Supplementary Figure 1.  
In contrast, the administration of oxaliplatin caused predominantly downregulation of DEGs (For 
full list of DEGs following vincristine administration see Supplementary Table S2). Following 
oxaliplatin treatment, 60 DEGs were up-regulated and 235 DEGs were down-regulated (Figure 
2C and D). Among the down-regulated genes (log2fold change < - 1) were Snhg1 (small 
nucleolar RNA host gene 1), Meg3 (Maternally expressed gene 3), Malat1 (Metastasis-
associated lung adenocarcinoma transcript 1), Mirg (miRNA containing gene) and Wasf1 (WAS 
protein family, member 1). Interestingly, none of these down-regulated genes has been 
associated with altered pain responses to date. Among the up-regulated genes (log2fold change > 
1) were Ptgds (Prostaglandin-H2 D-isomerase), Vtn (Vitronectin) and Cldn11 (Claudin 11) 
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(Figure 2C), of which only Prostaglandin-H2 D-isomerase has been linked to painful states [5]. 
The direct and secondary interactions between DEGs following oxaliplatin administration are 
shown in Supplementary Figure 2. 
Similarly, following cisplatin treatment, 72 DEG were up-regulated and 184 DEG were down-
regulated (Figure 2E and F) (For full list of DEGs following vincristine administration see 
Supplementary Table S3). Among the down-regulated genes (log2fold change < - 1) were Pclo 
(Piccolo (presynaptic cytomatrix protein)), Zfhx2 (Zinc finger homeobox 2), Raph1 (Ras 
association (RalGDS/AF-6) and pleckstrin homology domains 1) and Syn1 (Synapsin I); some of 
which have been associated with altered pain perception and neuropathic pain in previous studies 
[23; 75; 76; 78]. The highly upregulated DEGs (log2fold change > 1) included Lcn2 (Lipocalin-
2), Hba-a2 (Hemoglobin alpha, adult chain 2) and Alas2 (Aminolevulinic acid synthase 2, 
erythroid), of which only Lipocalin-2 have been associated with altered pain behavior [29]. The 
direct and secondary interactions between DEGs following cisplatin administration are shown in 
Supplementary Figure 3. 
As dorsal root ganglia are a heterogeneous tissue containing the cell bodies of peripheral nerves, 
epithelial cells, fibroblasts, glial cells and immune cells, DEGs discovered following treatment 
with vincristine, oxaliplatin and cisplatin cannot be unequivocally assigned to sensory neurons 
alone. We thus next performed cell type enrichment analysis by CTEN, a web-based analytical 
platform using a highly expressed, cell specific (HECS) gene database to identify enriched cell 
types from transcriptomic data [68], to gain insights into cell-specific effects of vincristine, 
oxaliplatin or cisplatin.  
Cell type enrichment analysis showed that DEGs after vincristine administration significantly 
overlap with gene profiles of bone marrow and of immune cells (Figure 3A and 
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Supplementary Table 4). Specifically, the highest scores were assigned to bone marrow 
(157.5), bone (147.0), granulocytes (84.1), macrophages (41.7), spleen (38.8) and microglia 
(27.5), suggesting that treatment with vincristine leads to gene expression changes consistent 
with neuro-inflammatory mechanisms. Surprisingly, DEGs caused by oxaliplatin administration 
overlapped with gene profiles of neuronal cells, as the highest scores were assigned to cerebral 
cortex (9.4), hypothalamus (8.2), cerebellum (8.1), amygdala (6.6), spinal cord (5.4) and dorsal 
root ganglia (4.5). However, oxaliplatin treatment did not result in altered expression of genes 
that are associated with the immune system, suggesting a predominant neuropathic phenotype 
(Figure 3B and Supplementary Table 4). In contrast, DEGs associated with cisplatin treatment 
showed mixed cell profiles overlapping with those seen in both vincristine- and oxaliplatin-
treated animals, with the highest scores assigned to bone marrow (13.6), bone (11.4), 
granulocytes ((10.5), cerebral cortex (9.4), dorsal root ganglia (9.2) and spinal cord (8.4) (Figure 
3C and Supplementary Table 4).  
To further identify shared genes that may contribute to the pathology of chemotherapy-induced 
neuropathy irrespective of the causative agent, we compared DEGs identified after vincristine, 
oxaliplatin or cisplatin administration (Figure 4A-G). Vincristine and cisplatin shared 27 DEGs 
(Figure 4E), vincristine and oxaliplatin shared 7 DEGs (Figure 4F); and oxaliplatin and 
cisplatin shared the highest amount of DEGs, in total 171 (Figure 4D and Supplementary 
Table 5). Interestingly, we identified 5 genes that were shared between vincristine, oxaliplatin 
and cisplatin: aminolevulinic acid synthase 2, erythroid (Alas2), hemoglobin, beta adult t chain 
(Hbb-bt), integrin beta 2-like (Itgb2l), lymphocyte antigen 6 complex, locus C2 (Ly6c2) and 
nuclear receptor subfamily 4, group A, member 3 (Nr4a3) (Figure 4G and Supplementary 
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Table 5). Interestingly, none of the above-mentioned genes have been associated with pain 
pathology to date, and their functional roles in CIPN are unclear. 
To further explore the functional roles of DEGs after vincristine, oxaliplatin or cisplatin 
administration, we performed Gene Set Enrichment analysis using the GSEA tool [72]. For each 
drug, the number of genes overlapping with the curated C5 gene set (k) and the false discovery 
rate q-value as a measure of statistical significance are shown in Table 2 (only top 20 GO terms 
for each drug are shown). Additionally, we compared the 60 most significant GO terms to 
identify similarities shared between the three experimental groups (Figure 4B and C). All three 
experimental groups shared 2 GO terms; regulation of transport and response to external 
stimulus. Vincristine and oxaliplatin shared 6 GO terms; regulation of cell death, regulation of 
cell proliferation, regulation of multicellular organismal development, regulation of transport, 
response to endogenous stimulus and response to external stimulus. Vincristine and cisplatin 
shared 13 GO terms; including defense response, immune system process, locomotion and 
response to external stimulus. Oxaliplatin and cisplatin shared 15 GO terms, including cell 
projection organization, macromolecular complex assembly, neurogenesis and vesicle mediated 
transport (for full lists of shared GO terms see Table 3). 
Remarkably, 46% of DEGs after vincristine administration overlapped with immune system-
associated processes, 22.6% with regulation of cellular processes, 4.4% with cellular transport 
processes and none with neuronal processes or DNA and RNA processing (Figure 4C). In 
contrast, 25% of DEGs after oxaliplatin administration overlapped with DNA and RNA 
processing, 18% with regulation of cellular processes, 13% with cellular transport processes, 
12% with neuronal processes and only 5% of immune system associated processes (Figure 4C). 
Moreover, 20% of cisplatin induced DEGs overlap with regulation of cellular processes, 14% 
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with immune system associated processes, 10% with cellular transport processes, 9% with 
neuronal processes and 8% with DNA and RNA processing (Figure 4C).  
Discussion 
Although chemotherapy-induced peripheral neuropathy (CIPN) is one of the major causes of 
treatment cessation in patients receiving vincristine, oxaliplatin or cisplatin, no currently 
available treatments adequately control or prevent the development of this side effect [20; 71]. 
With the exception of cold-induced hyperalgesia in patients receiving oxaliplatin, the pain-
related symptoms of CIPN are similar across all three drugs (Table 1). Importantly, these 
differences are replicated in animal models of CIPN, with oxaliplatin but not cisplatin and 
vincristine causing cold allodynia, while all compounds caused mechanical hypersensitivity 
(Figure 1). However, the mechanisms leading to development of CIPN are poorly understood, 
multi-factorial and appear to be drug specific [71]. In the present study, we performed 
transcriptomic analysis of gene expression changes in dorsal root ganglia from mice treated with 
vincristine, oxaliplatin or cisplatin, with a view to gain an understanding of the differential and 
shared mechanisms that contribute to the development of CIPN. 
One major finding of our analysis was that vincristine treatment caused predominantly up-
regulation of genes, whereas gene expression was mostly down-regulated after treatment with 
oxaliplatin and cisplatin. This may be due to local recruitment of immune cells to the DRGs 
following vincristine administration. Vincristine has been shown to cause neuronal inflammation 
[9; 81] and altered excitability of peripheral neurons by affecting the immune system [8; 9; 31; 
33; 55; 79]. Consistent with these neuro-inflammatory effects, cell type enrichment analysis 
(Cten) and gene set enrichment analysis (GSEA) showed that vincristine administration is 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
accompanied with gene expression changes typical for immune cell recruitment and 
inflammation.  
Among the highly upregulated genes following vincristine administration were Atf3 (Activating 
Transcription Factor 3), a general marker for nerve damage and regeneration following injury of 
DRG neurons [40], and the neuropeptide neurotensin, which is known to be involved in neuronal 
damage [25; 48]. One of the highly down-regulated genes was Ms4a1, encoding the Membrane 
Spanning 4-Domains A1, also called the CD20 antigen, the target of several monoclonal 
antibodies (e.g. rituximab) used in the treatment of B cell lymphomas and leukemias. The precise 
function of CD20 remains unknown, however this putative calcium channel is expressed on the 
surface of pro-B lymphocytes through to mature B-lymphocytes, where its expression is 
terminated upon differentiation into plasma cells [74]. As Ms4a1 is only expressed in a very 
limited number of DRG neurons, the observed gene expression changes likely arise from the 
population of non-neuronal cells in whole DRGs.  
Cisplatin-induced gene expression changes incorporated both neuropathic and inflammatory 
elements, with CTEN analysis of cisplatin-exposed DRGs identifying overlaps with both 
neuronal and immune cells. Additionally, GSEA identified overlaps with GO Biological 
processes involved in neuronal damage and the immune system, supporting a mixed neuro-
immune pathology induced by cisplatin. Overlaps of both cisplatin and oxaliplatin, but not 
vincristine, with DNA processing is consistent with the mechanisms of action of these drugs; 
with vincristine inhibiting the assembly of β-tubulin [21], while the platinum derivates 
oxaliplatin and cisplatin bind to DNA and interfere with replication, transcription and cell cycle 
[1; 12; 19; 87]. 
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In contrast to vincristine and cisplatin, inflammatory mechanisms did not appear to contribute 
significantly to oxaliplatin-induced neuropathy. Specifically, GSEA of the oxaliplatin-treated 
group identified GO biological processes associated with neuronal damage and DNA and RNA 
processing. Furthermore, CTEN of the oxaliplatin-treated groups identified overlaps with 
neuronal cells, but not with immune cells. This result was somewhat surprising, as oxaliplatin-
induced peripheral neuropathy has previously been associated with changes in immune system 
activation and regulation. For example; oxaliplatin-induced mechanical hyperalgesia and 
epidermal nerve fibre loss were prevented by the tetracycline minocycline, an antibiotic known 
to inhibit macrophages/monocytes and microglia [6; 16; 41; 63]. Oxaliplatin also led to increased 
levels of pro-inflammatory cytokines (IL-6, IL-8, IL1β, TNF-α), which in turn can lead to 
sensitization of nociceptors [8; 18; 26; 27; 28; 36; 37; 43; 44; 47; 60; 79; 84; 85]. It is possible 
that in oxaliplatin-induced neuropathy, neuronal damage and the associated changes in gene 
expression precede inflammatory processes, which may drive development of more chronic 
neuropathy symptoms. In addition, further research is required to determine if altered expression 
of inflammatory genes induced by treatment with vincristine and cisplatin causally contribute to 
the development of CIPN, or are rather a reflection of glial or immune cell damage in DRGs. 
Although the symptoms of peripheral neuropathy following oxaliplatin, cisplatin or vincristine 
treatment appear to be relatively similar in nature, only few DEGs were shared between all 
agents. Curiously, these genes included integrin β2 like protein and lymphocyte antigen complex 
6, which are predominately expressed on immune cells [22; 64], while – perhaps disappointingly 
– no pain- or neuropathy-related genes were identified. 
Nonetheless, several DEGs emerging after treatment with individual agents have previously been 
associated with pain processing. For example, knockout of the Neurotensin receptor 1 or 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Endothelin Converting Enzyme 2 led to altered pain perception in mice [49; 51], while knockout 
of the Cholecystokinin B receptor was connected to functional TLR4 deficiency and a 
consequent reduction of neuropathic pain in mice [34]. Additionally, Activating Transcription 
Factor 3, Cholecystokinin B Receptor and Steroidogenic Acute Regulatory Protein were all 
found to be upregulated after neuronal injury, including spinal cord injury, burn injury and after 
treatment of C57BL6 mice with the chemotherapy agent paclitaxel [10; 31; 46; 83]. Similarly, 
expression of the gene encoding for Piccolo (presynaptic cytomatrix protein) was significantly 
increased in rat spinal dorsal horn after vincristine treatment and in a model of orofacial 
neuropathic pain [75; 76]. Additionally, Zinc finger homeobox 2 knockout mice (Zfhx2 
-/-
 ) show 
deficits in pain sensitivity and a point mutation in Zfhx2 gene results in deficits in pain sensitivity 
and is associated with insensitive phenotype in humans [23]. Whether DEGs that have no known 
association with pain are novel targets for the treatment or prevention of CIPN remains to be 
determined.  
Additionally, oxaliplatin administration caused upregulation of genes including Prostaglandin-
H2 D-isomerase, an enzyme that catalyzes the conversion of Prostaglandin H2 in Prostaglandin 
D2. This has previously been found to be upregulated in the serum of neuropathic rats after 
chronic constriction injury [5]. Interestingly, although treatment with oxaliplatin caused cold 
allodynia (Figure 2) and previous studies suggested the involvement of Transient receptor 
potential cation channel, subfamily A, member 1 (TRPA1) in oxaliplatin-induced cold allodynia 
[2; 52; 57; 82; 86], no changes in expression of thermosensitive TRP channels were observed in 
the present study. It is possible that these differences are due to differences in methods, 
analytical techniques or environmental influences. Alternatively, gene expression changes 
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occurring as a consequence of oxaliplatin treatment may enhance neuronal excitability to cold 
stimuli in the absence of changes in the gene expression of thermosensitive TRP channels. 
 
Conclusion 
We present a detailed overview of gene expression changes in dorsal root ganglia induced by 
treatment with the chemotherapeutic agents vincristine, oxaliplatin and cisplatin. Overall, 
vincristine predominantly caused dysregulation of genes associated with immune system 
processes, whereas oxaliplatin caused dysregulation of genes associated with neuronal function, 
and cisplatin resulted in gene expression changes consistent with a mixed inflammatory and 
neuropathic pathology. These findings may provide insight into novel drug targets for treatment 
of CIPN. 
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Figure Legends 
Figure 1: Behavioral comparison of CIPN symptoms induced by oxaliplatin, cisplatin and 
vincristine. Mechanical, heat and cold responses were assessed in C57BL/6 mice treated with 
oxaliplatin, cisplatin and vincristine. (A) Oxaliplatin, cisplatin and vincristine led to a significant 
reduction in mechanical paw withdrawal compared with vehicle-treated control. (B) Cisplatin 
caused heat hyperalgesia while vincristine caused heat hypoalgesia and oxaliplatin had no effect 
on heat withdrawal thresholds assessed using the Hargreaves test. (C) Only treatment with 
oxaliplatin caused hypersensitivity to cooling, reflected by an increased number of paw flinches 
at 10 °C. Data are presented as mean ± S.E.M. from n=6 animals. * P < 0.05 compared with 
control by One-way ANOVA. 
Figure 2: Analysis of differentially expressed genes in mouse lumbar dorsal root ganglia L3- L5 
following vincristine, oxaliplatin and cisplatin administration. Volcano plot of all DEGs 
following vincristine (A) , oxaliplatin (B) and cisplatin (C) administration showing the most 
highly upregulated (log2fold change > 1) or downregulated (log2fold change < - 1) genes. Only 
genes with Padj < 0.05 and log2-foldchange greater than 1 or smaller than -1 were used for 
further analysis. Vincristine administration caused the up-regulation of 323 DEG and the down-
regulation of 45 DEG (D); oxaliplatin administration caused the up-regulation of 60 DEGs and 
the down-regulation of 235 DEGs (E) and cisplatin administration caused the up-regulation of 72 
DEGs and the down-regulation of 184 EGs (F). 
Figure 3: Cell type specific effect of vincristine, oxaliplatin and cisplatin. Cell type enrichment 
analysis of differentially expressed genes in lumbal dorsal root ganglia L3-5 following 
vincristine (A) , oxaliplatin (B) and cisplatin (C) administration. Cell type enrichment analysis 
was performed using the CTen tool. The score is generated using one-sided, Fisher's Exact test 
for enrichment and it is shown as the -log10 of the Benjamini-Hochberg (BH) adjusted P-values. 
Scores > 20 optimally minimize the false positive rate (FPR).  
Figure 4: Venn diagrams of (A) differentially expressed genes (Padj <0.05; log2foldchange ±1) 
or (B) identified GO biological terms shared between vincristine, oxaliplatin or cisplatin. GO 
terms were identified using the gene set enrichment analysis of DEGs with C5 curated gene set 
(biological process) and were computed with FDR q value setting < 0.05 and top 60 gene set 
overlaps were shown. C) The five most significant gene set enrichment signatures of the DEGs 
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after vincristine, oxaliplatin or cisplatin administration show predominant inflammatory 
processes after vincristine treatment, while DEGs following oxaliplatin and cisplatin 
administration overlap predominantly with DNA and RNA processing. Network analysis, 
generated with STRING version 10, showing interactions between differentially expressed genes 
shared between (D) oxaliplatin and cisplatin, (E) vincristine and cisplatin, (F) vincristine and 
oxaliplatin and (G) vincristine, oxaliplatin and cisplatin. Diagrams are presented in confidence 
view, and only interactions with at least medium or high confidence of evidence are shown. 
Proteins were clustered using the Markov Cluster Algorithm with inflation parameter of 1.8.  
Table 1: Peripheral neuropathy symptoms in humans. Paresthesia: An abnormal sensation that is 
not unpleasant. Dysesthesia: An abnormal unpleasant sensation. Hyperesthesia: Increased 
sensitivity to stimulation. Hypoesthesia: Decreased sensitivity to stimulation. Neuralgia: Pain in 
the distribution of a nerve or nerves. +: Effect observed in humans; - : Effects not or extremely 
rarely observed in humans. 
Table 2: Gene set enrichment analysis of differentially expressed genes in mouse lumbar dorsal 
root ganglia L3-L5 following vincristine, oxaliplatin and cisplatin administration. GSEA overlap 
analysis of DEGs with C5 curated gene set (biological process). K show the number of DEGs in 
overlap and FDR q-value indicate the significance of each overlap with the GO term and only 20 
most significant overlaps are shown. VC: vincristine, OX: oxaliplatin, CIS: cisplatin, GO: gene 
ontology, FDR: false discovery rate, red: lowest values, yellow: 50% values, green: highest 
values. GO terms are alphabetically sorted. 
Table 3: GO terms shared between vincristine and/or oxaliplatin and/or cisplatin. GO terms were 
identified using the gene set enrichment analysis of DEGs with C5 curated gene set (biological 
process) and were computed with FDR q value setting < 0.05 and top 60 gene set overlaps were 
shown. 
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Table 1: Peripheral neuropathy symptoms in humans. Paresthesia: An abnormal sensation that is 
not unpleasant. Dysesthesia: An abnormal unpleasant sensation. Hyperesthesia: Increased 
sensitivity to stimulation. Hypoesthesia: Decreased sensitivity to stimulation. Neuralgia: Pain in 
the distribution of a nerve or nerves. +: Effect observed in humans; - : Effects not or extremely 
rarely observed in humans. 
Symptom 
Vincristine Oxaliplatin Cisplatin 
E
ff
ec
t 
R
ef
. 
E
ff
ec
t 
R
ef
. 
E
ff
ec
t 
R
ef
. 
Hypoesthesia / numbness + [32; 54] + [56] + [42] 
Hyperesthesia / hypersensitivity + [39] 
+ (esp to 
cold) 
[56] -  
Paresthesia / dysesthesia + [32; 54] 
+ (often cold-
related) 
[56; 65] + [42] 
Burning sensation + [4] + [50] + [61] 
Neuralgia / pain + [54] + [56] + [42] 
Jaw pain + [24] + [80] -  
Arthralgia (joint pain) or bone 
pain 
+ [24] + [35] -  
Myalgia (muscle pain) or muscle 
cramps 
+ [24] + [56] + [69] 
Decreased vibration sense + [77] + [58] + [42] 
Hyporeflexia / areflexia + [54] + [58] + [42] 
Muscle weakness + [32; 54] + [35] -  
Gait abnormalities (difficulties 
walking) 
+ [24; 77] + [58] + [42] 
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Table 2: Gene set enrichment analysis of differentially expressed genes in mouse lumbar dorsal 
root ganglia L3-L5 following vincristine, oxaliplatin and cisplatin administration. GSEA overlap 
analysis of DEGs with C5 curated gene set (biological process). K show the number of DEGs in 
overlap and FDR q-value indicate the significance of each overlap with the GO term and only 20 
most significant overlaps are shown. VC: vincristine, OX: oxaliplatin, CIS: cisplatin, GO: gene 
ontology, FDR: false discovery rate, red: lowest values, yellow: 50% values, green: highest 
values. GO terms are alphabetically sorted. 
GO term 
VC # 
Genes in 
Overlap 
(k) 
VC 
FDR q-
value 
 
OX # 
Genes in 
Overlap (k) 
OX 
FDR 
q-
value 
 
CIS # 
Genes in 
Overlap 
(k) 
CIS 
FDR 
q-
value 
GO_CELL_MOTILITY 34 
2.35E-
15 
0 0 0 0 
GO_CELLULAR_MACROMOLECULAR
_ 
COMPLEX_ASSEMBLY 
0 0 0 0 18 
4.12E
-07 
GO_CELLULAR_RESPONSE_TO_ORGA
NIC_ 
SUBSTANCE 
56 
4.53E-
20 
0 0 0 0 
GO_CENTRAL_NERVOUS_SYSTEM_ 
DEVELOPMENT 
0 0 18 
9.11
E-06 
0 0 
GO_CHROMATIN_ASSEMBLY_OR_ 
DISASSEMBLY 
0 0 0 0 12 
6.45E
-09 
GO_CYTOSKELETON_ORGANIZATION 0 0 0 0 22 
4.46E
-09 
GO_DEFENSE_RESPONSE 65 
3.47E-
37 
0 0 28 
2.14E
-10 
GO_DEFENSE_RESPONSE_TO_OTHER_ 
ORGANISM 
0 0 0 0 18 
3.19E
-09 
GO_DNA_CONFORMATION_CHANGE 0 0 0 0 12 
4.27E
-07 
GO_DNA_PACKAGING 0 0 0 0 11 
1.78E
-07 
GO_FAT_CELL_DIFFERENTIATION 0 0 7 
7.07
E-05 
0 0 
GO_HOMEOSTATIC_PROCESS 42 
2.87E-
15 
0 0 0 0 
GO_IMMUNE_RESPONSE 64 
6.68E-
39 
0 0 0 0 
GO_IMMUNE_SYSTEM_DEVELOPMEN
T 
31 4.52E- 0 0 0 0 
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17 
GO_IMMUNE_SYSTEM_PROCESS 103 
1.61E-
61 
0 0 38 
8.98E
-12 
GO_INFLAMMATORY_RESPONSE 33 
3.6E-
22 
0 0 0 0 
GO_INNATE_IMMUNE_RESPONSE 35 
3.75E-
20 
0 0 0 0 
GO_LEUKOCYTE_MIGRATION 25 
1.25E-
19 
0 0 0 0 
GO_LOCOMOTION 46 
2.69E-
21 
0 0 0 0 
GO_MACROMOLECULAR_COMPLEX_ 
ASSEMBLY 
0 0 0 0 26 
6.49E
-08 
GO_MOVEMENT_OF_CELL_OR_ 
SUBCELLULAR_COMPONENT 
51 
3.82E-
23 
0 0 29 
1.54E
-10 
GO_MRNA_METABOLIC_PROCESS 0 0 16 
2.98
E-06 
0 0 
GO_MRNA_PROCESSING 0 0 15 
2.90
E-07 
0 0 
GO_NEGATIVE_REGULATION_OF_CE
LL_ 
DEATH 
0 0 17 
4.15
E-05 
0 0 
GO_NEGATIVE_REGULATION_OF_GE
NE_ 
EXPRESSION 
0 0 22 
6.81
E-05 
0 0 
GO_NEUROGENESIS 0 0 22 
2.77
E-05 
26 
6.49E
-08 
GO_POSITIVE_REGULATION_OF_ 
BIOSYNTHETIC_PROCESS 
0 0 29 
2.90
E-07 
0 0 
GO_POSITIVE_REGULATION_OF_GEN
E_ 
EXPRESSION 
0 0 29 
1.88
E-07 
29 
6.49E
-08 
GO_POSITIVE_REGULATION_OF_ 
IMMUNE_SYSTEM_PROCESS 
44 
1.15E-
23 
0 0 0 0 
GO_POSITIVE_REGULATION_OF_MUL
TICELLULAR_ORGANISMAL_PROCES
S 
49 
5.67E-
20 
0 0 0 0 
GO_POSITIVE_REGULATION_OF_ 
RESPONSE_TO_STIMULUS 
58 
1.22E-
20 
0 0 0 0 
GO_POSITIVE_REGULATION_OF_ 
TRANSCRIPTION_FROM_RNA_ 
POLYMERASE_II_PROMOTER 
0 0 22 
2.21
E-07 
0 0 
GO_PROTEIN_COMPLEX_BIOGENESIS 0 0 0 0 23 
1.21E
-07 
GO_PROTEIN_COMPLEX_SUBUNIT_ 
ORGANIZATION 
0 0 0 0 31 
2.14E
-10 
GO_PROTEIN_DNA_COMPLEX_SUBUN
IT_ 
ORGANIZATION 
0 0 0 0 12 
8.26E
-08 
GO_REGULATION_OF_ANATOMICAL_ 
STRUCTURE_MORPHOGENESIS 
0 0 19 
1.75
E-05 
0 0 
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GO_REGULATION_OF_CELL_DEATH 0 0 25 
1.44
E-06 
0 0 
GO_REGULATION_OF_CELLULAR_ 
LOCALIZATION 
0 0 0 0 24 
2.03E
-07 
GO_REGULATION_OF_IMMUNE_ 
RESPONSE 
38 
1.77E-
18 
0 0 0 0 
GO_REGULATION_OF_IMMUNE_ 
SYSTEM_PROCESS 
56 
1.66E-
25 
0 0 0 0 
GO_REGULATION_OF_TRANSCRIPTIO
N_ 
FROM_RNA_POLYMERASE_II_ 
PROMOTER 
0 0 35 
7.54
E-11 
0 0 
GO_REGULATION_OF_TRANSPORT 0 0 30 
1.81
E-07 
36 
8.98E
-12 
GO_REGULATION_OF_VESICLE_ 
MEDIATED_TRANSPORT 
0 0 16 
1.81
E-07 
15 
2.82E
-07 
GO_RESPONSE_TO_BIOTIC_STIMULU
S 
0 0 0 0 21 
6.49E
-08 
GO_RESPONSE_TO_CYTOKINE 32 
1.56E-
15 
0 0 0 0 
GO_RESPONSE_TO_ENDOGENOUS_ 
STIMULUS 
0 0 24 
3.68
E-06 
0 0 
GO_RESPONSE_TO_EXTERNAL_ 
STIMULUS 
64 
1.97E-
26 
0 0 34 
1.91E
-10 
GO_RNA_PROCESSING 0 0 18 
5.09
E-06 
0 0 
GO_RNA_SPLICING 0 0 13 
2.67
E-06 
0 0 
GO_RNA_SPLICING_VIA_ 
TRANSESTERIFICATION_REACTIONS 
0 0 10 
4.84
E-05 
0 0 
GO_TAXIS 28 
1.01E-
16 
0 0 0 0 
GO_TRANSCRIPTION_FROM_RNA_ 
POLYMERASE_II_PROMOTER 
0 0 17 
4.10
E-06 
0 0 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 3: GO terms shared between vincristine and/or oxaliplatin and/or cisplatin. GO terms were 
identified using the gene set enrichment analysis of DEGs with C5 curated gene set (biological 
process) and were computed with FDR q value setting < 0.05 and top 60 gene set overlaps were 
shown. 
Vincristine & Oxaliplatin & Cisplatin 
GO term 
GO_REGULATION_OF_TRANSPORT 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
  
Vincristine & Oxaliplatin 
GO term 
GO_REGULATION_OF_CELL_DEATH 
GO_REGULATION_OF_CELL_PROLIFERATION 
GO_REGULATION_OF_MULTICELLULAR_ORGANISMAL_DEVELOPMENT 
GO_REGULATION_OF_TRANSPORT 
GO_RESPONSE_TO_ENDOGENOUS_STIMULUS 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
  
Vincristine & Cisplatin 
GO term 
GO_DEFENSE_RESPONSE 
GO_DEFENSE_RESPONSE_TO_OTHER_ORGANISM 
GO_IMMUNE_SYSTEM_PROCESS 
GO_LOCOMOTION 
GO_MOVEMENT_OF_CELL_OR_SUBCELLULAR_COMPONENT 
GO_POSITIVE_REGULATION_OF_CELL_COMMUNICATION 
GO_POSITIVE_REGULATION_OF_RESPONSE_TO_STIMULUS 
GO_REGULATION_OF_IMMUNE_SYSTEM_PROCESS 
GO_REGULATION_OF_SECRETION 
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GO_REGULATION_OF_TRANSPORT 
GO_RESPONSE_TO_BACTERIUM 
GO_RESPONSE_TO_BIOTIC_STIMULUS 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
  
Oxaliplatin & Cisplatin 
GO term 
GO_CELL_PROJECTION_ORGANIZATION 
GO_MACROMOLECULAR_COMPLEX_ASSEMBLY 
GO_NEUROGENESIS 
GO_POSITIVE_REGULATION_OF_BIOSYNTHETIC_PROCESS 
GO_POSITIVE_REGULATION_OF_GENE_EXPRESSION 
GO_POSITIVE_REGULATION_OF_TRANSPORT 
GO_PROTEIN_COMPLEX_BIOGENESIS 
GO_PROTEIN_COMPLEX_SUBUNIT_ORGANIZATION 
GO_REGULATION_OF_CELLULAR_LOCALIZATION 
GO_REGULATION_OF_CLATHRIN_MEDIATED_ENDOCYTOSIS 
GO_REGULATION_OF_ORGANELLE_ORGANIZATION 
GO_REGULATION_OF_TRANSPORT 
GO_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT 
GO_RESPONSE_TO_EXTERNAL_STIMULUS 
GO_VESICLE_MEDIATED_TRANSPORT 
 
 
 
